CSS
MCID: ESN020
MIFTS: 54

Eosinophilic Granulomatosis with Polyangiitis (CSS)

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Immune diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Eosinophilic Granulomatosis with Polyangiitis

MalaCards integrated aliases for Eosinophilic Granulomatosis with Polyangiitis:

Name: Eosinophilic Granulomatosis with Polyangiitis 53 59 37
Churg-Strauss Syndrome 53 59 73
Granulomatous Allergic Angiitis 53 59
Egpa 53 59
Allergic Angiitis and Granulomatosis 53
Allergic Granulomatous and Angiitis 53
Churg-Strauss Vasculitis 53
Allergic Granulomatosis 53
Css 53

Characteristics:

Orphanet epidemiological data:

59
eosinophilic granulomatosis with polyangiitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),<1/1000000 (Sweden),1-9/100000 (France),1-9/100000 (Sweden),<1/1000000 (United Kingdom),1-9/100000 (Norway),<1/1000000 (Spain),1-9/100000 (Australia),1-9/1000000 (Europe),1-9/100000 (Worldwide),<1/1000000 (Norway),1-9/1000000 (Germany),1-9/1000000 (Lithuania),1-9/1000000 (France),1-9/100000 (Germany),1-9/100000 (Japan); Age of onset: Adolescent,Adult,Elderly; Age of death: adolescent,adult,elderly,young Adult;

Classifications:



Summaries for Eosinophilic Granulomatosis with Polyangiitis

NIH Rare Diseases : 53 Eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome) is a condition characterized by asthma, high levels of eosinophils (a type of white blood cell that helps fight infection), and inflammation of small to medium sized blood vessels (vasculitis). The inflamed vessels can affect various organ systems including the lungs, gastrointestinal tract, skin, heart and nervous system. The exact cause of eosinophilic granulomatosis with polyangiitis is unknown, but it is thought to be an autoimmune disorder. Treatment may involve the use of glucocorticoids (steroids) and/or other immunosuppressive therapies. As of December 2017, mepolizumab (Nucala) became the first therapy approved specifically to treat eosinophilic granulomatosis with polyangiitis. When added to traditional steroid or immunosuppressive therapy, mepolizumab has been found to increase remission rate and time in remission for 50% of people with eosinophilic granulomatosis with polyangiitis.

MalaCards based summary : Eosinophilic Granulomatosis with Polyangiitis, also known as churg-strauss syndrome, is related to granulomatosis with polyangiitis and microscopic polyangiitis. An important gene associated with Eosinophilic Granulomatosis with Polyangiitis is FCGR3B (Fc Fragment Of IgG Receptor IIIb), and among its related pathways/superpathways is Phagosome. The drugs Azathioprine and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and heart, and related phenotypes are hypertension and gait disturbance

Wikipedia : 76 Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg�??Strauss syndrome (CSS) or... more...

Related Diseases for Eosinophilic Granulomatosis with Polyangiitis

Diseases related to Eosinophilic Granulomatosis with Polyangiitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 194)
# Related Disease Score Top Affiliating Genes
1 granulomatosis with polyangiitis 31.6 FCGR3B MPO
2 microscopic polyangiitis 29.6 FCGR3B MPO
3 churg-strauss syndrome 11.8
4 allergic angiitis 11.8
5 anca-associated vasculitis 11.7
6 coffin-siris syndrome 1 11.4
7 autoimmune lymphoproliferative syndrome 11.2
8 granulomatous angiitis 10.6
9 glomerulonephritis 10.6
10 vasculitis 10.6
11 retinal artery occlusion 10.5
12 central retinal artery occlusion 10.5
13 wells syndrome 10.5
14 asthma 10.5
15 neuropathy 10.5
16 crescentic glomerulonephritis 10.4
17 myocarditis 10.4
18 myocardial infarction 10.4
19 branch retinal artery occlusion 10.4
20 viral infectious disease 10.4
21 aspergillosis 10.3
22 thrombosis 10.3
23 cholecystitis 10.3
24 hypereosinophilic syndrome 10.3
25 cardiac conduction defect 10.3
26 gastroenteritis 10.3
27 acalculous cholecystitis 10.3
28 iga glomerulonephritis 10.3
29 purpura 10.3
30 rapidly progressive glomerulonephritis 10.3
31 dacryoadenitis 10.3
32 systemic polyarteritis nodosa 10.3
33 hepatitis 10.2
34 endocarditis 10.2
35 allergic bronchopulmonary aspergillosis 10.2
36 polyneuropathy 10.2
37 mononeuritis multiplex 10.2
38 peripheral nervous system disease 10.2
39 thrombophilia due to thrombin defect 10.2
40 anemia, autoimmune hemolytic 10.2
41 nonarteritic anterior ischemic optic neuropathy 10.2
42 focal segmental glomerulosclerosis 1 10.2
43 angina pectoris 10.2
44 arthritis 10.2
45 focal segmental glomerulosclerosis 10.2
46 hemolytic anemia 10.2
47 ischemic optic neuropathy 10.2
48 retinal vein occlusion 10.2
49 mononeuropathy 10.2
50 optic neuritis 10.2

Graphical network of the top 20 diseases related to Eosinophilic Granulomatosis with Polyangiitis:



Diseases related to Eosinophilic Granulomatosis with Polyangiitis

Symptoms & Phenotypes for Eosinophilic Granulomatosis with Polyangiitis

Human phenotypes related to Eosinophilic Granulomatosis with Polyangiitis:

59 32 (show top 50) (show all 53)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypertension 59 32 frequent (33%) Frequent (79-30%) HP:0000822
2 gait disturbance 59 32 frequent (33%) Frequent (79-30%) HP:0001288
3 dysphagia 59 32 frequent (33%) Frequent (79-30%) HP:0002015
4 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
5 respiratory insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0002093
6 arthritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001369
7 malabsorption 59 32 occasional (7.5%) Occasional (29-5%) HP:0002024
8 gastroesophageal reflux 59 32 occasional (7.5%) Occasional (29-5%) HP:0002020
9 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0000083
10 proteinuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0000093
11 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
12 cranial nerve paralysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0006824
13 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
14 subcutaneous nodule 59 32 occasional (7.5%) Occasional (29-5%) HP:0001482
15 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
16 acrocyanosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001063
17 hypertrophic cardiomyopathy 59 32 frequent (33%) Frequent (79-30%) HP:0001639
18 myocardial infarction 59 32 occasional (7.5%) Occasional (29-5%) HP:0001658
19 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
20 transient ischemic attack 59 32 occasional (7.5%) Occasional (29-5%) HP:0002326
21 weight loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0001824
22 hemiplegia/hemiparesis 59 32 occasional (7.5%) Occasional (29-5%) HP:0004374
23 peripheral neuropathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0009830
24 sinusitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000246
25 congestive heart failure 59 32 hallmark (90%) Very frequent (99-80%) HP:0001635
26 abnormality of the pleura 59 32 frequent (33%) Frequent (79-30%) HP:0002103
27 autoimmunity 59 32 hallmark (90%) Very frequent (99-80%) HP:0002960
28 venous thrombosis 59 32 frequent (33%) Frequent (79-30%) HP:0004936
29 hypopigmented skin patches 59 32 frequent (33%) Frequent (79-30%) HP:0001053
30 myalgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003326
31 intestinal obstruction 59 32 occasional (7.5%) Occasional (29-5%) HP:0005214
32 glomerulopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0100820
33 hematuria 59 32 frequent (33%) Frequent (79-30%) HP:0000790
34 hemoptysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002105
35 purpura 59 32 hallmark (90%) Very frequent (99-80%) HP:0000979
36 asthma 59 32 hallmark (90%) Very frequent (99-80%) HP:0002099
37 myocarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012819
38 endocarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100584
39 skin rash 59 32 frequent (33%) Frequent (79-30%) HP:0000988
40 cough 59 32 occasional (7.5%) Occasional (29-5%) HP:0012735
41 urticaria 59 32 hallmark (90%) Very frequent (99-80%) HP:0001025
42 vasculitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002633
43 recurrent intrapulmonary hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0006535
44 papule 59 32 occasional (7.5%) Occasional (29-5%) HP:0200034
45 nasal polyposis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100582
46 myositis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100614
47 cutis marmorata 59 32 occasional (7.5%) Occasional (29-5%) HP:0000965
48 central nervous system degeneration 59 32 hallmark (90%) Very frequent (99-80%) HP:0007009
49 eosinophilia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001880
50 pulmonary infiltrates 59 32 hallmark (90%) Very frequent (99-80%) HP:0002113

MGI Mouse Phenotypes related to Eosinophilic Granulomatosis with Polyangiitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.13 FCGR3B IL27 MPO
2 immune system MP:0005387 8.8 FCGR3B IL27 MPO

Drugs & Therapeutics for Eosinophilic Granulomatosis with Polyangiitis

Drugs for Eosinophilic Granulomatosis with Polyangiitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4,Phase 3,Early Phase 1 446-86-6 2265
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-24-8 5755
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 83-43-2 6741
6
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Not Applicable 302-25-0
7
leucovorin Approved Phase 4,Phase 2 58-05-9 6006 143
8
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Not Applicable 2921-57-5
9
Methotrexate Approved Phase 4,Phase 2 59-05-2, 1959-05-2 126941
10
Mycophenolic acid Approved Phase 4 24280-93-1 446541
11
rituximab Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 174722-31-7 10201696
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-30-3 6037
13
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Not Applicable 2920-86-7
14 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
20 Antimetabolites Phase 4,Phase 3,Phase 2
21 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
22 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
23 Vitamin B9 Phase 4,Phase 2
24 Prednisolone acetate Phase 4,Phase 3,Not Applicable
25 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
26 Anti-Infective Agents Phase 4,Not Applicable
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
28 Neuroprotective Agents Phase 4,Phase 3,Not Applicable
29 Antiemetics Phase 4,Phase 3,Not Applicable
30 Vitamin B Complex Phase 4,Phase 2
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
32 Folic Acid Antagonists Phase 4,Phase 2
33 Methylprednisolone acetate Phase 4,Phase 3,Not Applicable
34 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
35 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
36 Dermatologic Agents Phase 4,Phase 2,Not Applicable
37 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
38 Protective Agents Phase 4,Phase 3,Not Applicable
39 Autonomic Agents Phase 4,Phase 3,Not Applicable
40 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2
41 Folate Phase 4,Phase 2
42 Antitubercular Agents Phase 4
43 Antibiotics, Antitubercular Phase 4
44 Anti-Bacterial Agents Phase 4
45 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable
46 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable
47 Pharmaceutical Solutions Phase 3
48 Immunoglobulins, Intravenous Phase 3
49 gamma-Globulins Phase 3
50 Rho(D) Immune Globulin Phase 3

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors Unknown status NCT00399399 Phase 4 azathioprine;cyclophosphamide
2 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
3 Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Recruiting NCT03164473 Phase 4 Rituximab;Azathioprine;Placebo-rituximab;Placebo-azathioprine
4 A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis Completed NCT02020889 Phase 3 Placebo
5 Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
6 Rituximab in Eosinophilic Granulomatosis With Polyangiitis Recruiting NCT02807103 Phase 3 Rituximab;Placebo-rituximab;Cyclophosphamide;Placebo-cyclophosphamide
7 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Recruiting NCT02836496 Phase 3 Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules
8 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Active, not recruiting NCT03298061 Phase 3 Mepolizumab;Prednisolone
9 Intravenous Immunoglobulin After Relapse in Vasculitis Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
10 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
11 Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome Completed NCT00527566 Phase 1, Phase 2
12 Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome Completed NCT00716651 Phase 2 mepolizumab
13 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
14 Steroids and Methotrexate to Treat Systemic Vasculitis Completed NCT00001256 Phase 2 prednisone and methotrexate
15 Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study Recruiting NCT02947945 Phase 2 Reslizumab
16 Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study Recruiting NCT03010436 Phase 2 Benralizumab
17 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Not yet recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
18 Rituxan in Churg Strauss Syndrome With Renal Involvement Terminated NCT00424749 Phase 2 Rituximab;Prednisone
19 Abatacept in ANCA Associated Vasculitis Terminated NCT00482066 Phase 2 Abatacept (Orencia)
20 Hematopoietic Stem Cell Support in Vasculitis Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
21 PRO Development for ANCA Associated Vasculitis Unknown status NCT01729624
22 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Unknown status NCT01066208
23 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 Not Applicable anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
24 Survey of Patients With Idiopathic Orbital Inflammation Syndrome Unknown status NCT01443000
25 RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Completed NCT00307593 Not Applicable Infliximab;Rituximab
26 Educational Needs of Patients With Systemic Vasculitis Completed NCT02190929
27 The ANCA Vasculitis Questionnaire (AAV-PRO©) Completed NCT02507024
28 Vasculitis Illness Perception (VIP) Study Completed NCT02190916
29 Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290
30 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
31 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
32 Eosinophilic Granulomatosis With Polyangiitis Cohort Recruiting NCT03036670
33 Determining Disease Activity Biomarkers in Individuals With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Recruiting NCT00315380
34 Pediatric Vasculitis Initiative Recruiting NCT02006134
35 VCRC Tissue Repository Recruiting NCT02967068
36 Vasculitis Pregnancy Registry Recruiting NCT02593565
37 One-Time DNA Study for Vasculitis Recruiting NCT01241305
38 Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Recruiting NCT03004326
39 Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Recruiting NCT03698071 Not Applicable
40 Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE) Recruiting NCT03373045
41 NUCALA® Special Drug Use Investigation (EGPA, Long-term) Active, not recruiting NCT03557060 Nucala
42 Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) Active, not recruiting NCT01862068
43 VCRC Patient Contact Registry Patient-Reported Data Validation Study Enrolling by invitation NCT02190942
44 Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome Terminated NCT02728271 Early Phase 1

Search NIH Clinical Center for Eosinophilic Granulomatosis with Polyangiitis

Genetic Tests for Eosinophilic Granulomatosis with Polyangiitis

Anatomical Context for Eosinophilic Granulomatosis with Polyangiitis

MalaCards organs/tissues related to Eosinophilic Granulomatosis with Polyangiitis:

41
Skin, Lung, Heart, T Cells, Bone, Spinal Cord, Colon

Publications for Eosinophilic Granulomatosis with Polyangiitis

Articles related to Eosinophilic Granulomatosis with Polyangiitis:

(show top 50) (show all 557)
# Title Authors Year
1
Flare of eosinophilic granulomatosis with polyangiitis related to pregnancy: Case report and review of the literature. ( 30456168 )
2019
2
Eosinophilic granulomatosis with polyangiitis in children: Data from the French RespiRareAr cohort. ( 29943913 )
2018
3
Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies. ( 29611001 )
2018
4
Multiple Cerebral Infarctions Due to Patent Foramen Ovale in a Patient with Eosinophilic Granulomatosis with Polyangiitis. ( 29373226 )
2018
5
Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis. ( 29908086 )
2018
6
A Case of dilated Cardiomyopathy with Eosinophilic Granulomatosis with Polyangiitis in which Active Myocardial Inflammation was Only Detected by Endomyocardial Biopsy. ( 29709930 )
2018
7
Mepolizumab Treatment of Pediatric Eosinophilic Granulomatosis With Polyangiitis. ( 29466544 )
2018
8
Comparison of findings on thoracic computed tomography with the severity and duration of bronchial asthma in patients with eosinophilic granulomatosis with polyangiitis. ( 29857992 )
2018
9
Eosinophilic granulomatosis with polyangiitis and laryngeal involvement: review of the literature and a cross-sectional prospective experience. ( 29888684 )
2018
10
Overall Disability Sum Score for Clinical Assessment of Neurological Involvement in Eosinophilic Granulomatosis With Polyangiitis. ( 29652700 )
2018
11
A Rare Case of Eosinophilic Granulomatosis with Polyangiitis Associated with Cryoglobulinemia Presenting with a Bullous Skin Eruption of the Lower Limbs. ( 29560002 )
2018
12
Histopathological Findings and Increased D-Dimer Are Predictive Factors of Systemic Thromboses in Eosinophilic Granulomatosis With Polyangiitis. ( 29979194 )
2018
13
Focus on the Involvement of the Nose and Paranasal Sinuses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Nasal Cytology Reveals Infiltration of Eosinophils as a Very Common Feature. ( 29393242 )
2018
14
Polyps, grommets and eosinophilic granulomatosis with polyangiitis. ( 29310745 )
2018
15
Longterm Outcomes of 188 Japanese Patients with Eosinophilic Granulomatosis with Polyangiitis. ( 29907668 )
2018
16
Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review. ( 29766394 )
2018
17
HBsAg-negative and anti-HBc-positive in eosinophilic granulomatosis with polyangiitis: a retrospective pilot study. ( 29754328 )
2018
18
Eosinophilic granulomatosis with polyangiitis: A case report. ( 29428428 )
2018
19
Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. ( 29637936 )
2018
20
Eosinophilic Granulomatosis with Polyangiitis Manifested by Cholecystitis and Mononeuritis Multiplex: A Case Report. ( 29892153 )
2018
21
Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report. ( 29564565 )
2018
22
Angioimmunoblastic T-cell lymphoma mimicking eosinophilic granulomatosis with polyangiitis (Churg-Strauss). ( 29966769 )
2018
23
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors. ( 29936437 )
2018
24
Development of Hypertrophic Pachymeningitis in a Patient With Antineutrophil Cytoplasmic Antibody-Negative Eosinophilic Granulomatosis With Polyangiitis. ( 29485545 )
2018
25
Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. ( 30170804 )
2018
26
Churg-Strauss Syndrome or Eosinophilic Granulomatosis with Polyangiitis: Exuberant Classic Clinical Picture of a Rare Disease. ( 30057533 )
2018
27
Ophthalmic Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome): A Systematic Review of the Literature. ( 30134390 )
2018
28
Churg-Strauss Syndrome Presenting As Acute Necrotizing Eosinophilic Myocarditis. Concise review of the literature. ( 30179138 )
2018
29
Usefulness of Cardiac Magnetic Resonance in the Diagnosis of Löffler Endocarditis Secondary to Eosinophilic Granulomatosis with Polyangiitis. ( 30146590 )
2018
30
Eosinophilic granulomatosis with polyangiitis without respiratory symptoms or asthma in an adolescent: case report and literature review. ( 29189887 )
2018
31
Intracranial vasculitis in eosinophilic granulomatosis with polyangiitis. ( 29901786 )
2018
32
Pulmonary embolism and deep vein thrombosis in eosinophilic granulomatosis with polyangiitis successfully treated with rivaroxaban. ( 29998056 )
2018
33
Conjunctival Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) in a Young Adult Male With Persistent Ptosis. ( 30048387 )
2018
34
Response to: 'Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors' by Delyon et al. ( 30054370 )
2018
35
Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report. ( 30073971 )
2018
36
Eosinophilic Myocarditis Demonstrated Using Cardiac Magnetic Resonance Imaging in a Patient with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Disease). ( 30112268 )
2018
37
Endothelial dysfunction in patients with eosinophilic granulomatosis with polyangiitis. ( 30132147 )
2018
38
Eosinophilic granulomatosis with polyangiitis mimicking peripheral T-cell lymphoma, not otherwise specified. ( 30153088 )
2018
39
Sputum ANCA in Serum ANCA-Negative Eosinophilic Granulomatosis with Polyangiitis (eGPA). ( 30179583 )
2018
40
Eosinophilic Granulomatosis with Polyangiitis: Clinical Pathology Conference and Review. ( 30197069 )
2018
41
Spinal Cord Injury Secondary to Eosinophilic Granulomatosis With Polyangiitis: Case Report and Review of the Literature. ( 30222627 )
2018
42
Successfully treated eosinophilic granulomatosis with polyangiitis relapse presenting as myocarditis and followed by multimodality imaging. ( 30279934 )
2018
43
Eosinophilic Granulomatosis with Polyangiitis (EGPA) with an Unusual Manifestation of Mid-Ventricular Obstruction Caused by Endocardial Thrombus. ( 30293983 )
2018
44
Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. ( 30308057 )
2018
45
C-Reactive protein as a diagnostic tool in differential diagnosis of hypereosinophilic syndrome and antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis. ( 30317003 )
2018
46
Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). ( 30404114 )
2018
47
An Atypical Case of Non-asthmatic Eosinophilic Granulomatosis with Polyangiitis Finally Diagnosed by Tissue Biopsy. ( 30449779 )
2018
48
A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis. ( 30497438 )
2018
49
Non-asthmatic and HCV-seropositive eosinophilic granulomatosis with polyangiitis complicated by multiple intracerebral haemorrhages: a case study. ( 30499447 )
2018
50
Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases. ( 30524647 )
2018

Variations for Eosinophilic Granulomatosis with Polyangiitis

Expression for Eosinophilic Granulomatosis with Polyangiitis

Search GEO for disease gene expression data for Eosinophilic Granulomatosis with Polyangiitis.

Pathways for Eosinophilic Granulomatosis with Polyangiitis

Pathways related to Eosinophilic Granulomatosis with Polyangiitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.81 FCGR3B MPO

GO Terms for Eosinophilic Granulomatosis with Polyangiitis

Cellular components related to Eosinophilic Granulomatosis with Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 8.8 FCGR3B IL27 MPO

Biological processes related to Eosinophilic Granulomatosis with Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 8.62 FCGR3B MPO

Sources for Eosinophilic Granulomatosis with Polyangiitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....